百克生物
(688276)
| 流通市值：93.36亿 | | | 总市值：159.47亿 |
| 流通股本：2.42亿 | | | 总股本：4.14亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 392,478,600.47 | 442,179,928.33 | 459,406,166.62 | 572,473,569.86 |
| 应收票据及应收账款 | 1,589,143,642.96 | 1,567,228,875.46 | 1,365,085,229.11 | 922,534,914.73 |
| 其中：应收票据 | - | 3,569,680.8 | - | - |
| 应收账款 | 1,589,143,642.96 | 1,563,659,194.66 | 1,365,085,229.11 | 922,534,914.73 |
| 预付款项 | 40,459,542.23 | 30,954,490.4 | 29,508,111.27 | 33,560,238.92 |
| 其他应收款合计 | 3,730,188.35 | 2,323,982.49 | 3,342,606.08 | 5,476,507.05 |
| 应收股利 | 941,290 | - | - | - |
| 存货 | 232,973,921.68 | 199,017,837.02 | 201,151,711.2 | 241,318,191.68 |
| 其他流动资产 | 5,270,356.9 | 2,908,816.28 | 19,049,430.02 | 9,427,127.6 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,264,056,252.59 | 2,244,613,929.98 | 2,077,543,254.3 | 1,784,790,549.84 |
| 非流动资产: | | | | |
| 长期股权投资 | 34,284,057.32 | 34,864,426.95 | 34,707,957.36 | 34,610,160.77 |
| 其他权益工具投资 | 164,713,438.25 | 172,706,558.2 | 182,695,775.87 | 185,012,382.11 |
| 固定资产 | 964,459,810.94 | 984,207,934.13 | 907,824,843.28 | 701,205,352.73 |
| 在建工程 | 1,151,608,600.76 | 1,101,106,243.68 | 1,117,213,730.92 | 1,225,711,256.93 |
| 无形资产 | 337,096,753.95 | 347,453,415.64 | 356,421,279.25 | 372,191,972.15 |
| 开发支出 | - | - | 14,142,773.97 | 10,734,765.29 |
| 长期待摊费用 | 26,968,689.84 | 29,257,414.74 | 30,103,824.25 | 32,321,799.68 |
| 递延所得税资产 | 90,649,179.32 | 90,968,890.37 | 56,063,071.22 | 48,530,575.18 |
| 其他非流动资产 | 56,862,814.68 | 41,058,849.05 | 15,843,379 | 31,584,035.68 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,826,643,345.06 | 2,801,623,732.76 | 2,715,016,635.12 | 2,641,902,300.52 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,090,699,597.65 | 5,046,237,662.74 | 4,792,559,889.42 | 4,426,692,850.36 |
| 流动负债: | | | | |
| 短期借款 | 65,404,084.66 | 20,472,018.39 | - | 52,276,121.71 |
| 应付票据及应付账款 | 23,501,514.43 | 17,487,654.81 | 21,540,344.75 | 32,395,525.23 |
| 其中：应付票据 | - | - | 3,829,500 | - |
| 应付账款 | 23,501,514.43 | 17,487,654.81 | 17,710,844.75 | 32,395,525.23 |
| 合同负债 | 1,312,987.82 | 283,079.03 | 4,995,514.77 | 1,818,309.24 |
| 应付职工薪酬 | 41,353,074.63 | 88,550,868.95 | 52,702,832.26 | 40,117,261.93 |
| 应交税费 | 32,096,451.03 | 58,980,141.01 | 45,989,731.26 | 8,187,666.24 |
| 其他应付款合计 | 734,553,591.68 | 718,913,038.34 | 760,635,757.14 | 658,946,540.91 |
| 其中:应付利息 | - | - | - | 43,563.43 |
| 应付股利 | - | - | 25,723,227.3 | 25,723,227.3 |
| 其他流动负债 | 102,422,857.51 | 110,179,066.41 | 51,663,569.3 | 20,654.73 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,000,644,561.76 | 1,014,865,866.94 | 937,527,749.48 | 793,762,079.99 |
| 非流动负债: | | | | |
| 预计负债 | 172,925.69 | 172,925.69 | 565,550.8 | 565,550.8 |
| 递延收益 | 9,588,208.89 | 9,856,247.33 | 4,664,470.68 | 4,952,066.63 |
| 递延所得税负债 | 956,093.04 | 981,046.79 | 1,006,000.54 | 1,030,954.29 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 10,717,227.62 | 11,010,219.81 | 6,236,022.02 | 6,548,571.72 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,011,361,789.38 | 1,025,876,086.75 | 943,763,771.5 | 800,310,651.71 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 412,840,698 | 412,840,698 | 412,840,698 | 412,840,698 |
| 资本公积 | 1,826,354,139.67 | 1,820,357,794.27 | 1,809,233,801.2 | 1,798,580,522.69 |
| 其他综合收益 | -39,448,289.96 | -31,863,111.41 | -22,388,583.23 | -14,439,475.21 |
| 盈余公积 | 486,349,744.2 | 486,349,744.2 | 378,495,876.4 | 378,495,876.4 |
| 未分配利润 | 1,393,241,516.36 | 1,332,676,450.93 | 1,270,614,325.55 | 1,050,904,576.77 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 4,079,337,808.27 | 4,020,361,575.99 | 3,848,796,117.92 | 3,626,382,198.65 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,079,337,808.27 | 4,020,361,575.99 | 3,848,796,117.92 | 3,626,382,198.65 |
| 负债和股东权益合计 | 5,090,699,597.65 | 5,046,237,662.74 | 4,792,559,889.42 | 4,426,692,850.36 |
| 公告日期 | 2024-04-20 | 2024-03-20 | 2023-10-24 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |